6-氨基-1,2,3,4-四氢-异喹啉盐酸盐 | 175871-42-8

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氨基-1,2,3,4-四氢-异喹啉盐酸盐
• 中文别名: 6-氨基-1,2,3,4-四氢异喹啉盐酸盐
• 英文名称: 6-amino-1,2,3,4-tetrahydroisoquinoline hydrochloride
• 英文别名: 1,2,3,4-tetrahydroisoquinoline-6-amine monohydrochloride；1,2,3,4-Tetrahydroisoquinolin-6-amine hydrochloride；1,2,3,4-tetrahydroisoquinolin-6-amine;hydrochloride
• CAS: 175871-42-8
• 化学式: C₉H₁₂N₂*ClH
• 分子量: 184.669
• InChiKey: OVCSYUPAHMVXJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.34
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-氨基-1,2,3,4-四氢-异喹啉盐酸盐 、 对甲基苯磺酰异氰酸酯 在 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 以7%的产率得到N-[(4-methylphenyl)sulfonyl]-6-({[(4-methylphenyl)sulfonyl]-carbamoyl}amino)-3,4-dihydroisoquinoline-2(1H)-carboxamide
  参考文献：
  名称：

  WO2008/38051

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氨基-2-N-BOC-1,2,3,4-四氢-异喹啉 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 15.0h， 生成 6-氨基-1,2,3,4-四氢-异喹啉盐酸盐
  参考文献：
  名称：

  [EN] SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION
  [FR] PETITES MOLÉCULES DIRIGÉES CONTRE LE CÉRÉBLON POUR AMÉLIORER LA FONCTION DES LYMPHOCYTES T EFFECTEURS

  摘要：

  披露了针对小脑蛋白以增强效应T细胞功能的小分子。还披露了制造这些分子的方法以及使用它们治疗各种疾病状态的方法。

  公开号：

  WO2017161119A1

文献信息

• Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2116546A1

  公开（公告）日：2009-11-11

  The invention relates to compounds having pharmacological activity towards the 5-HT6 receptor, and more particularly to some N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT6 is involved.

  该发明涉及具有对5-HT6受体具有药理活性的化合物，更特别地涉及一些N-苯基-2,3-二氢咪唑[2,1-b]噻唑-5-磺酰胺衍生物，以及制备这些化合物的方法，包括含有它们的药物组合物，以及它们用于治疗和/或预防5-HT6参与的疾病。
• Bicyclic amidine dervatives as inhibitors of nitric oxide synthetase
  申请人：Astra Aktiebolag

  公开号：US05807886A1

  公开（公告）日：1998-09-15

  Compounds of the formula (I) ##STR1## wherein D represents a 5-membered heterocyclic aromatic ring containing 1 to 4 heteroatoms selected from O, N or S, optionally substituted at a carbon atom by halogen, trifluoromethyl, alkyl C1 to 6, nitro, cyano, and which is connected to the remainder of the compound of formula (I) through a carbon atom; A represents (N(X) or CH(--(CH.sub.2).sub.m --NXY); U represents NH, O or CH.sub.2 ; V represents (CH.sub.2).sub.b ; a, b,m, X and Y are as defined in the specification, together with processes for their preparation and compositions containing them. Compounds of formula (I) are nitric oxide synthetase inhibitors and are useful in therapy.

  式(I)的化合物 ##STR1## 其中D代表含有1至4个来自O、N或S的杂原子的5元杂环芳香环，可选地在一个碳原子上被卤素、三氟甲基、烷基C1至C6、硝基、氰基取代，并且通过一个碳原子连接到式(I)化合物的其余部分；A代表(N(X)或CH(--(CH.sub.2).sub.m --NXY)；U代表NH、O或CH.sub.2；V代表(CH.sub.2).sub.b；a、b、m、X和Y的定义如规范中所述，以及它们的制备方法和含有它们的组合物。式(I)的化合物是一氧化氮合酶抑制剂，可用于治疗。
• Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1837332A1

  公开（公告）日：2007-09-26

  The present invention relates to substituted tetrahydroisoquinoline compounds of general formula I, a process for their preparation, medicaments comprising said substituted tetrahydroisoquinoline compounds as well as the use of said substituted tetrahydroisoquinoline compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及通式I的取代四氢异喹啉化合物，其制备方法，包含所述取代四氢异喹啉化合物的药物以及使用所述取代四氢异喹啉化合物制备药物，这些药物特别适用于预防和/或治疗部分通过5-HT6受体介导的疾病或紊乱。
• Ion Channel Modulators & Uses Thereof
  申请人：Lawton Geoff

  公开号：US20090318423A1

  公开（公告）日：2009-12-24

  Compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH 2 or CH 2 CH 2 , R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO 2 , R5R7NCO, R5R7NSO 2 , R5SO 2 NR7CO or CO 2 R8, Y is R6CO, R6SO 2 , R6R7NCO, R6R7NSO 2 , R6SO 2 NR7CO or CO 2 R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, are of use in the prophylaxis or treatment of diseases and conditions in which Kv1.x channels are involved, such as lower urinary tract disorders, cardiovascular diseases and pain.

  通式（1）及其药理学上可接受的盐和前药的化合物：公式（1）中，A和B是CH2或 ，R1是氢，烷基，环烷基，芳基，芳基烷基或杂芳基烷基，R2，R3和R4从氢，烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，羟基或氰基中选择；X是R5CO，R5SO2，R5R7NCO，R5R7NSO2，R5SO2NR7CO或CO2R8，Y是R6CO，R6SO2，R6R7NCO，R6R7NSO2，R6SO2NR7CO或CO2R8，R5和R6是氢，烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，R7是氢，烷基，芳基或芳基烷基，R8是烷基，芳基，芳基烷基，烷氧基烷基，杂芳基或杂芳基烷基，用于预防或治疗Kv1.x通道参与的疾病和病状，如下尿路疾病，心血管疾病和疼痛。
• Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases
  申请人：Lawton Geoff

  公开号：US20110130383A1

  公开（公告）日：2011-06-02

  Use of compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH 2 or CH 2 CH 2 , R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO 2 , R5R7NCO, R5R7NSO 2 , R5SO 2 NR7CO or CO 2 R8, Y is R6CO, R6SO 2 , R6R7NCO, R6R7NSO 2 , R6SO 2 NR7CO or CO 2 R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, provided that when X is R5CO or R5SO 2 , then Y is not R6CO, R6SO 2 or R6R7NCO, in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunological disease.

  通式（1）及其药理学上可接受的盐和前药的化合物的使用：式（1）其中A和B是CH2或 ，R1是氢，烷基，环烷基，芳基，芳基烷基或杂芳基烷基，R2、R3和R4从氢，烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，羟基或氰基中选择；X是R5CO，R5SO2，R5R7NCO，R5R7NSO2，R5SO2NR7CO或CO2R8，Y是R6CO，R6SO2，R6R7NCO，R6R7NSO2，R6SO2NR7CO或CO2R8，R5和R6是氢，烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，R7是氢，烷基，芳基或芳基烷基，R8是烷基，芳基，芳基烷基，烷氧基烷基，杂芳基或杂芳基烷基，前提是当X是R5CO或R5SO2时，Y不是R6CO，R6SO2或R6R7NCO，用于预防或治疗炎症或免疫疾病的药物制剂的制造。